日期:
2020 年 — 2026 年
2020
2021
2022
2023
2024
2025
2026
影响因子:

Initial Phase I Safety Study of Gedatolisib plus Cofetuzumab Pelidotin for Patients with Metastatic Triple-Negative Breast Cancer

Gedatolisib 联合 Cofetuzumab Pelidotin 治疗转移性三阴性乳腺癌患者的初始 I 期安全性研究

Milan Radovich #, Jeffrey P Solzak #, Chao J Wang, Bradley A Hancock, Sunil Badve, Sandra K Althouse, Steven M Bray, Anna Maria V Storniolo, Tarah J Ballinger, Bryan P Schneider, Kathy D Miller

Genomic characterization of intrinsic and acquired resistance to cetuximab in colorectal cancer patients

结直肠癌患者对西妥昔单抗的内在和获得性耐药性的基因组表征

Steven M Bray, Jeeyun Lee, Seung Tae Kim, Joon Young Hur, Philip J Ebert, John N Calley, Isabella H Wulur, Thejaswini Gopalappa, Swee Seong Wong, Hui-Rong Qian, Jason C Ting, Jiangang Liu, Melinda D Willard, Ruslan D Novosiadly, Young Suk Park, Joon Oh Park, Ho Yeong Lim, Won Ki Kang, Amit Aggarwal,

Genomic Aberrations that Activate D-type Cyclins Are Associated with Enhanced Sensitivity to the CDK4 and CDK6 Inhibitor Abemaciclib

激活 D 型细胞周期蛋白的基因组畸变与对 CDK4 和 CDK6 抑制剂 Abemaciclib 的敏感性增强有关

Xueqian Gong, Lacey M Litchfield, Yue Webster, Li-Chun Chio, Swee Seong Wong, Trent R Stewart, Michele Dowless, Jack Dempsey, Yi Zeng, Raquel Torres, Karsten Boehnke, Cecilia Mur, Carlos Marugán, Carmen Baquero, Chunping Yu, Steven M Bray, Isabella H Wulur, Chen Bi, Shaoyou Chu, Hui-Rong Qian, Phili